 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Comparison of treatment-free survival (TFS) between nivolumab + ipilimumab and sunitinib in patients with advanced renal cell carcinoma (aRCC): results from Check-Mate 214

Clin Cancer Res: Comparison of treatment-free survival (TFS) between nivolumab + ipilimumab and sunitinib in patients with advanced renal cell carcinoma (aRCC): results from Check-Mate 214

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

acidity treatment

testosterone cypionate results

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The results of the randomized phase III clinical study Check-Mate 214 showed that in patients with advanced renal cell carcinoma (aRCC) with intermediate or poor prognostic risk of IMDC, nivolumab + ipilimumab significantly prolonged the OS of patients compared with sunitinib

Data analysis comes from the randomized Phase III CheckMate 214 trial, nivolumab + ipilimumab (n=550) vs sunitinib (n=546) for treatment of untreated advanced renal cell carcinoma (aRCC)

Data analysis comes from the randomized Phase III CheckMate 214 trial, nivolumab + ipilimumab (n=550) vs sunitinib (n=546) for untreated advanced renal cell carcinoma (aRCC)

Among 847 aRCC patients with intermediate or poor prognostic risk of IMDC, the 42-month OS rates in the nivolumab + ipilimumab group and sunitinib group were 52% and 39%, respectively

The 42-month average TFS of non-toxic patients in the nivolumab + ipilimumab group was longer than that of non-toxic patients in the sunitinib group (TFS without TRAEs ≥3: difference, 3.

Among the 249 patients with a good prognosis risk for IMDC, 70.

The results of the overall intent population are similar to those of the moderate/low risk population

In summary, studies have shown that regardless of the risk of aRCC patients, compared with the sunitinib group, non-toxic patients treated with nivolumab + ipilimumab have longer treatment-free survival (TFS)

Original source:

Regan MM, Jegede OA, Mantia CM, et al.

Regan MM, Jegede OA, Mantia CM, et al.
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Clin Cancer Res.
2021 Nov 10.
doi: 10.
1158/1078-0432.
CCR-21-2283.
Epub ahead of print.
PMID: 34759043.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.